Table S2: Non-treatment naïve/pubertal patient characteristics at baseline, with or without Laron syndrome (Enrolled population)

	Non-NPP-Laron syndrome (N = 17)		Non-NPP-non-Laron syndrome (N = 87)		P values[a]
	N[b]		N[b]		
Female, *n* (%)	17	7 (41.2)	87	28 (32.2)	0.473[c]
95% CI		21.6; 64.0		23.3; 42.6	
Age at first injection, years	17		87		0.272[w]
Mean (SD [95% CI])		12.78 (3.73 [10.86; 14.70])		11.43 (3.58 [10.67; 12.20])	
Median (Q1; Q3)		12.16 (10.72; 15.29)		12.25 (8.74; 13.93)	
Height, SDS	15		77		0.011[w]
Mean (SD [95% CI])		−4.63 (1.51 [−5.47; −3.79])		−3.61 (1.20 [−3.88; −3.34])	
Median (Q1; Q3)		−4.93 (−5.89; −3.30)		−3.25 (−4.33; −2.84)	
Height velocity, cm/year	12		52		0.884[w]
Mean (SD [95% CI])		4.43 (1.23 [3.65; 5.21])		4.70 (1.84 [4.19; 5.21])	
Median (Q1; Q3)		4.57 (3.69; 5.18)		4.53 (3.70; 5.60)	
Weight, SDS	15		79		0.036[w]
Mean (SD [95% CI])		−2.34 (1.28 [−3.05; −1.63])		−3.28 (1.54 [−3.62; −2.93])	
Median (Q1; Q3)		−2.42 (−3.37; −1.17)		−2.92 (−4.10; −2.34)	
BMI, SDS	15		71		<0.001[w]

	b		b		p
Mean (SD [95% CI])		0.86 (1.56 [−0.00; 1.73])		−0.97 (1.38 [−1.30; −0.65])	
Median (Q1; Q3)		0.81 (−0.45; 1.85)		−0.93 (−1.57; −0.27)	
Mother's height, cm	16		76		-
Mean (SD [95% CI])		158.1 (10.2 [152.7; 163.5])		157.5 (9.2 [155.4; 159.6])	
Median (Q1; Q3)		158.1 (148.7; 167.5)		158.0 (151.5; 163.6)	
Father's height, cm	17		76		-
Mean (SD [95% CI])		173.2 (5.8 [170.2; 176.2])		171.4 (8.2 [169.6; 173.3])	
Median (Q1; Q3)		172.0 (170.0; 178.0)		171.5 (165.3; 177.5)	
IGF-1, ng/mL	13		78		0.153[w]
Mean (SD [95% CI])		261.41 (205.25 [137.38; 385.44])		148.74 (144.66 [116.12; 181.35])	
Median (Q1; Q3)		246.00 (62.00; 462.00)		105.50 (60.00; 171.10)	
Peak stimulated GH level, ng/mL	9		52		<0.001[w]
Mean (SD [95% CI])		62.77 (37.09 [34.25; 91.28])		23.95 (50.31 [9.94; 37.96])	
Median (Q1; Q3)		55.00 (40.00; 72.90)		15.10 (7.45; 23.25)	
Primary diagnosis: SPIGFD[†], *n* (%)	17	17 (100)	87	63 (72.4)	-
95% CI		81.6; 100		62.2; 80.7	
History of hypoglycaemia, *n* (%)	17	5 (29.4)	87	5 (5.7)	0.010[f]
95% CI		13.3; 53.1		2.5; 12.8	

Data are median Q1; Q3 unless stated otherwise. [†]including Laron syndrome, as reported by the investigator. [a]Non-NPP-Laron syndrome versus Non-NPP-non-Laron syndrome. [b]Number of patients with available data; (c) Chi-square test; (f) Fisher's test; (w) Wilcoxon test. BMI, body mass index; GH, growth

hormone; IGF-1; insulin-like growth factor-1; NPP, treatment-naïve and prepubertal; SD, standard deviation; SDS, standard deviation score; SPIGFD, severe primary IGF-1 deficiency.